drugset
drugset / Trial / NCT00774813

Nexalin Therapy for the Treatment of Depressive Symptoms

NCT00774813 ↗

Phase 2 Completed 120 enrolled Kalaco Scientific, Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

The primary objectives of this Phase II study are to demonstrate the safety of Nexalin Therapy and to investigate the efficacy of Nexalin Therapy.

Timeline

Start
2007-10
Primary completion
2008-05
Completion
2008-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator Citalopram Small molecule — —

Indications

depressive disorder